Advisory Research Inc. increased its position in shares of Intersect ENT Inc (NASDAQ:XENT) by 58.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 74,112 shares of the medical equipment provider’s stock after buying an additional 27,480 shares during the period. Advisory Research Inc. owned 0.25% of Intersect ENT worth $2,401,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Wells Fargo & Company MN boosted its holdings in shares of Intersect ENT by 64.1% during the 4th quarter. Wells Fargo & Company MN now owns 84,483 shares of the medical equipment provider’s stock worth $2,738,000 after buying an additional 33,007 shares during the period. Candriam Luxembourg S.C.A. bought a new stake in shares of Intersect ENT during the 4th quarter worth $1,069,000. Lisanti Capital Growth LLC boosted its holdings in shares of Intersect ENT by 150.5% during the 4th quarter. Lisanti Capital Growth LLC now owns 45,210 shares of the medical equipment provider’s stock worth $1,465,000 after buying an additional 27,165 shares during the period. Teacher Retirement System of Texas bought a new stake in shares of Intersect ENT during the 4th quarter worth $293,000. Finally, Jennison Associates LLC boosted its holdings in shares of Intersect ENT by 22.4% during the 4th quarter. Jennison Associates LLC now owns 2,036,202 shares of the medical equipment provider’s stock worth $65,973,000 after buying an additional 372,320 shares during the period. 87.44% of the stock is owned by institutional investors and hedge funds.
Shares of Intersect ENT Inc (NASDAQ:XENT) opened at $37.70 on Friday. Intersect ENT Inc has a 1-year low of $12.50 and a 1-year high of $38.30. The firm has a market cap of $1,110.00, a price-to-earnings ratio of -60.81 and a beta of 0.78.
XENT has been the subject of several recent analyst reports. Zacks Investment Research downgraded shares of Intersect ENT from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. Guggenheim reaffirmed a “buy” rating and set a $41.00 price objective on shares of Intersect ENT in a report on Friday, December 15th. Canaccord Genuity reaffirmed a “buy” rating and set a $36.00 price objective on shares of Intersect ENT in a report on Monday, December 11th. JPMorgan Chase & Co. raised shares of Intersect ENT from a “neutral” rating to an “overweight” rating in a report on Tuesday, January 2nd. Finally, BidaskClub downgraded shares of Intersect ENT from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $33.38.
ILLEGAL ACTIVITY NOTICE: “Intersect ENT Inc (XENT) Position Increased by Advisory Research Inc.” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://stocknewstimes.com/2018/02/17/intersect-ent-inc-xent-position-increased-by-advisory-research-inc.html.
About Intersect ENT
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.